Loughborough, UK: Further industry Award For Nemaura Pharma
Nemaura Pharma, the fast-growing UK medical technology company, is a finalist in the Medilink UK industry awards having received the Medilink East Midlands Innovation award for its unique transdermal drug delivery technologies. Included in the award citation is the Nemaura patented Micro-Patch™ product which provides a highly consistent and effective method for better delivery of biologics and vaccines through the skin using a low cost disposable device.
This latest recognition by life science sector experts comes just a year after Frost & Sullivan, the global growth strategy analysts, identified Nemaura’s drug delivery technologies as having the potential to revolutionize the way drugs are delivered into the body. Nemaura aims to be one of the leading pharmaceutical technologists in the skin drug delivery market, which is expected to grow at around 12% to a global value of over $95 billion by 2025
Dr Faz Chowdhury, Founding Director, commented: “Winning this Innovation Award has capped a busy and productive year for us. We have exciting plans for next year as we look to further expand the range of vaccines and biologics the Micro-Patch™ can deliver, and we are confident about engaging several new partners following the overwhelming response from potential licensees at this year’s BIO International Convention in San Diego.”
Nemaura joined the delegation to BIO 2017 which was supported by the Department for International Trade (DIT) and the development organisation, Midlands Engine.
Simon Hall, Director Exports & Investment Midlands Engine, said: “We are delighted that Nemaura are finalists in the Medilink UK industry awards which is a richly deserved achievement. Their pioneering pharmaceutical products are widely recognised across the sector for their innovation and this was further reinforced by the huge interest that was shown in them during the recent Midlands Engine visit to Bio 2017 in San Diego. The Midlands has an enviable reputation for pharma and healthcare, and the Department for International Trade will continue to work hard with companies in this field to help them exploit their expertise on the global stage.”
World-wide interest in Nemaura is being managed by the respected pharmaceutical expert and deal-maker Dr Werner Wessling who joined the team in April this year as Director of Strategic Alliances. His industry insight and extensive networks will make a significant contribution with annual license and royalty revenue expected to double by 2019.
Founded in 2005, Nemaura has patents secured or pending across multiple patent families and employs a multi-disciplinary team of medical device technologists and formulation experts based on the Loughborough University Science and Enterprise Park. Ambitious expansion plans mean the company is set to employ over 200 by 2025.
Dr Chowdhury explains: “With 22 drugs in development or commercialization, we are targeting revenues of over £100 million by 2025. Accolades from the likes of Frost & Sullivan and Medilink validate we are on the right track to commercial growth and success.”
ENDS
Media enquiries: Louise Third +44 (0) 7773 288342 pr@nemaura.co.uk
Business Development enquiries: David Scott + 44 (0)1509 222 912 bd@nemaura.co.uk
About Nemaura Pharma
www.nemaura.co.uk
Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.
The company employs multi-disciplinary teams of scientists and engineers working in cutting-edge innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.
The company has secured over £25m (over $30m) in licensing and development payments, and private investment. In addition, Nemaura has been awarded five highly competitive British Government grants worth £2 million, and the Frost & Sullivan 2016 Enabling Technology Leadership Award in Transdermal Drug Delivery.
This latest recognition by life science sector experts comes just a year after Frost & Sullivan, the global growth strategy analysts, identified Nemaura’s drug delivery technologies as having the potential to revolutionize the way drugs are delivered into the body. Nemaura aims to be one of the leading pharmaceutical technologists in the skin drug delivery market, which is expected to grow at around 12% to a global value of over $95 billion by 2025
Dr Faz Chowdhury, Founding Director, commented: “Winning this Innovation Award has capped a busy and productive year for us. We have exciting plans for next year as we look to further expand the range of vaccines and biologics the Micro-Patch™ can deliver, and we are confident about engaging several new partners following the overwhelming response from potential licensees at this year’s BIO International Convention in San Diego.”
Nemaura joined the delegation to BIO 2017 which was supported by the Department for International Trade (DIT) and the development organisation, Midlands Engine.
Simon Hall, Director Exports & Investment Midlands Engine, said: “We are delighted that Nemaura are finalists in the Medilink UK industry awards which is a richly deserved achievement. Their pioneering pharmaceutical products are widely recognised across the sector for their innovation and this was further reinforced by the huge interest that was shown in them during the recent Midlands Engine visit to Bio 2017 in San Diego. The Midlands has an enviable reputation for pharma and healthcare, and the Department for International Trade will continue to work hard with companies in this field to help them exploit their expertise on the global stage.”
World-wide interest in Nemaura is being managed by the respected pharmaceutical expert and deal-maker Dr Werner Wessling who joined the team in April this year as Director of Strategic Alliances. His industry insight and extensive networks will make a significant contribution with annual license and royalty revenue expected to double by 2019.
Founded in 2005, Nemaura has patents secured or pending across multiple patent families and employs a multi-disciplinary team of medical device technologists and formulation experts based on the Loughborough University Science and Enterprise Park. Ambitious expansion plans mean the company is set to employ over 200 by 2025.
Dr Chowdhury explains: “With 22 drugs in development or commercialization, we are targeting revenues of over £100 million by 2025. Accolades from the likes of Frost & Sullivan and Medilink validate we are on the right track to commercial growth and success.”
ENDS
Media enquiries: Louise Third +44 (0) 7773 288342 pr@nemaura.co.uk
Business Development enquiries: David Scott + 44 (0)1509 222 912 bd@nemaura.co.uk
About Nemaura Pharma
www.nemaura.co.uk
Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.
The company employs multi-disciplinary teams of scientists and engineers working in cutting-edge innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.
The company has secured over £25m (over $30m) in licensing and development payments, and private investment. In addition, Nemaura has been awarded five highly competitive British Government grants worth £2 million, and the Frost & Sullivan 2016 Enabling Technology Leadership Award in Transdermal Drug Delivery.